Skip to main content

Select Drug Profiles

FDA Approvals
The 2015 Oncology Drug Pipeline: Innovation Drives the Race to Cure Cancer
Dalia Buffery, MA, ABD
Read More
Perspectives
Did the “HEN” Lay a Rotten Egg?
David B. Nash, MD, MBA
Read More
Practice Management
Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis
J.D. Kleinke, Nancy McGee, DrPH
Stakeholder Perspective
Financing Drug Innovation: Cost versus Cure
by Joseph R. Antos, PhD
Read More
Practice Management
Demonstrating Value for Biosimilars: A Conceptual Framework
Sally Amanuel, MSc, MA, MBA, Paola Antonini, MD, PhD, Victoria Coutinho, MSc, PhD, Thomas Goss, PharmD, Zhihong Lai, PhD, Sotiris Rompas, Phd, Michael F. Murphy, MD, PhD
Stakeholder Perspective
Challenges Surrounding the New Biosimilars Landscape
by Michael Kleinrock
Read More
Practice Management
Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus
Machaon M. K. Bonafede, PhD, MPH, Arthi Chandran, MS, MPH, Laurence J Hirsch, MD, Betsy J Lahue, MPH, Sonali Nigam, MPH, Rita Saltiel-Berzin, RN, MPH, CDE, CHES
Stakeholder Perspective
Adherence to Antihyperglycemic Treatment Regimen Also Reduces Overall Costs
by Quang T. Nguyen, DO, FACE, FTOS
Read More
Conference Highlights AMCP
Payers’ Perspectives: Health Economics Outcomes in Managed Care
Charles Bankhead, Medical Writer
Read More
Perspectives
A Silver Anniversary of the Internet
David B. Nash, MD, MBA
Read More
Original Research
Cardiovascular-Related Healthcare Resource Utilization and Costs in Patients with Hypertension Switching from Metoprolol to Nebivolol
Stephanie Chen, PhD, An-Chen Fu, MS, BSPharm, Rahul Jain, PhD, Hiangkiat Tan, MS, BSPharm
Stakeholder Perspective
Moving Beyond Measures into Outcomes in Hypertension Research
by Michael F. Murphy, MD, PhD
Read More
Practice Management
Economic Burden of Opioid-Induced Constipation Among Long-Term Opioid Users with Noncancer Pain
Shelby Corman, PharmD, MS, BCPS, Xin Gao, PhD, Sizhu Liu, MS, Reema Mody, PhD,MBA, Haridarshan Patel, PharmD, Yin Wan, MS, BSPharm
Stakeholder Perspective
Opioid-Induced Constipation Associated with Considerable Economic Burden
by Matthew Mitchell, PharmD, MBA, FAMCP
Read More
Practice Management
The Cost of Unintended Pregnancies for Employer-Sponsored Health Insurance Plans
Gabriela Dieguez, FSA, MAAA, Amy W. Law, PharmD, Richard Lynen, MD, James Trussell, PhD, Bruce S. Pyenson, FSA, MAAA
Stakeholder Perspective
A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design
by F. Randy Vogenberg, PhD, FASHP
Read More
Page 132 of 244
Results 1311 - 1320 of 2434